Related Experiment Videos
In vitro activity of cefteram against predominantly enteropathogenic and glucose nonfermentative gram-negatives
P Hohl1, A von Graevenitz, J Zollinger-Iten
1Pharmaceutical Research Department, F. Hoffmann-La Roche, Basel, Switzerland.
Abstract:
Cefteram (T-2525), the free acid of the orally active cephalosporin ester cefteram pivoxil, was tested in vitro against 355 gram-negative clinical isolates of enteropathogenic and nonfermentative species. The compound was several times more active (w/w) against isolates belonging to the enteropathogenic Enterobacteriaceae and Vibrionaceae than against those belonging to the nonfermentative rods (excluding Pseudomonas aeruginosa).
Insights
Cefteram demonstrated higher in vitro activity against enteropathogenic bacteria like Enterobacteriaceae and Vibrionaceae compared to nonfermentative rods. This cephalosporin shows promise for targeting specific gram-negative pathogens.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Cefteram pivoxil is an orally active cephalosporin ester.
- Cefteram is the free acid form of cefteram pivoxil.
- Gram-negative bacteria pose significant clinical challenges.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity of cefteram.
- To compare cefteram's efficacy against different groups of gram-negative clinical isolates.
Main Methods:
- In vitro testing of cefteram (T-2525).
- Utilized 355 gram-negative clinical isolates.
- Included enteropathogenic and nonfermentative bacterial species.
Main Results:
- Cefteram exhibited significantly higher activity (weight/weight) against enteropathogenic Enterobacteriaceae and Vibrionaceae.
- Activity was notably lower against nonfermentative rods, with the exception of Pseudomonas aeruginosa.
Conclusions:
- Cefteram displays selective in vitro potency against key enteropathogenic gram-negative bacteria.
- The findings suggest potential therapeutic applications for cefteram in treating infections caused by these specific pathogens.